Transplantation in the patient with hepatitis C

Transplant International

Volumn 22, Issue 12, 2009, Pages 1117-1131

  Domínguez Gil, Beatriz ^a   Morales, Jose M ^b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b ORGANIZACIÓN NACIONAL DE TRASPLANTES   (Spain)

Author keywords

Hepatitis C; Kidney transplantation; Liver diseases; Organ and tissue procurement

Indexed keywords

ALPHA INTERFERON; CYCLOSPORIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; INTERFERON; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; POLYCLONAL ANTIBODY; RAPAMYCIN; RIBAVIRIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; VIRUS ANTIBODY; VIRUS RNA;

ACUTE GRAFT REJECTION; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC HEPATITIS; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME IMMUNOASSAY; GLOMERULONEPHRITIS; GLOMERULOPATHY; GRAFT DYSFUNCTION; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS VIREMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FIBROSIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MORTALITY; NEPHROTIC SYNDROME; POSTTRANSPLANT DIABETES MELLITUS; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROTEINURIA; REVIEW; VIREMIA; VIRUS REPLICATION;

GLOMERULONEPHRITIS; GRAFT REJECTION; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIVER DISEASES; LYMPHOPROLIFERATIVE DISORDERS; POSTOPERATIVE COMPLICATIONS; RISK; RISK FACTORS; TREATMENT OUTCOME;

EID: 70449094345     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2009.00926.x     Document Type: Review

References (116)

1. Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997 51 : 981.
2. Roth D. Hepatitis C virus: the nephrologist′s view. Am J Kidney Dis 1995 25 : 3.
3. Morales JM, Campistol JM. Transplantation in the patient with hepatitis C. J Am Soc Nephrol 2000 11 : 1343.
4. Vosnides GG. Hepatitis C in renal transplantation. Kidney Int 1997 52 : 843.
5. European Best Practice Guidelines for Renal Transplantation. Section I: Evaluation, selection and preparation of the potential recipient. Nephrol Dial Transplant 2000 15 (Suppl. 7 3.
6. KDIGO. Clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 2008 73 (Suppl. 109 S1.
7. Covic A, Abramowicz D, Bruchfeld A, et al. Endorsement of the kidney disease improving global outcomes (KDIGO) hepatitis C guidelines: a european renal best practice (ERBP) position statement. Nephrol Dial Transplant 2009 24 : 719.
8. Morales JM, Dominguez-Gil B, Sanz-Guajardo D, et al. The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol Dial Transplant 2004 19 (Suppl. 3 72.
9. PereIra BJ, Levey A. Hepatitis C in organ transplantation: its significance and influence on transplantation policies. Curr Opin Nephrol Hypertens 1993 2 : 912.
10. Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1998 53 : 1374.
11. Legendre C, Garrigue V, Le Bihan C, et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998 65 : 667.
12. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999 29 : 257.
13. Gentil MA, Rocha Jl, Rodriguez-Algarra G, et al. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus. Nephrol Dial Transplant 1999 14 : 2455.
14. Morales JM, Campistol JM, Andres A, Rodicio JM. Hepatitis C virus and renal transplantation. Curr Opin Nephrol Hypertens 1998 7 : 177.
15. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005 5 : 1452.
16. Roth D, Zucker K, Cirocco R, et al. A propsective study of hepatitis C virus infection in renal allograft recipients. Transplantation 1996 61 : 886.
17. Rostaing L, Izopet J, Sandres K, et al. Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation 2000 69 : 991.
18. Watashi K, Hijikata M, Hosaka M, et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003 38 : 1282.
19. Alric L, Di-Marino V, Selves J, et al. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology 2002 123 : 1494.
20. Muñoz de Bustillo E, Ibarrola C, Colina F, et al. Fibrosing cholestatic hepatitis in hepatitis C virus-infected transplant recipients. J Am Soc Nephrol 1998 9 : 1109.
21. Haem J, Berthoux P, Mosnier JF, et al. Clear evidence of the existence of healthy carriers of hepatitis C virus among renal transplant recipients. Transplantation 1996 62 : 699.
22. Luan FL, Schaubel DE, Hui Zhang H, et al. Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C. Transplantation 2008 85 : 1601.
23. Dominguez-Gil B, Esforzado N, Andres A, et al. Impact of induction with biologics in kidney transplant patients with a positive serology for hepatitis C: Long-term assessment in a collaborative study. Am J Transplant 2009 9 (Suppl 2 282.
24. Hoffmann CJ, Subramanian AK, Cameron AM, Engels EA. Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation. Transplantation 2008 86 : 784.
25. Glicklich D, Kapoian T. Should the hepatitis C positive end stage renal disease patient be transplanted? Seminar Dial 1996 9 : 5.
26. Kamar N, Rostaing L, Selves J, et al. Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant 2005 5 : 1704.
27. Zylberberg H, Nalpas B, Carnot F, et al. Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant 2002 17 : 129.
28. Perez RM, Ferreira AS, Medina-Pestana JO, et al. Is hepatitis C more aggressive in renal transplant patients than in patients with end-stage renal disease? J Clin Gastroenterol 2006 40 : 444.
29. Alric L, Kamar N, Bonnet D, et al. Comparison of liver stiffness, fibrotest and liver biosy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis. Transplant Int 2009 22 : 568.
30. Weclawiack H, Kamar N, Mehrenberger M, et al. Alpha-interferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts. Nephrol Dial Transplant 2008 23 : 1043.
31. Carbognin SJ, Solomon NM, Yeo FE, et al. Acute renal allograft rejection following pegylated IFN-alpha treatment for chronic HCV in a repeat allograft recipient on hemodialysis: a case report. Am J Transplant 2006 6 : 1746.
32. Kamar N, Ribes D, Izopet J, Rostaing L. Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis awaiting a kidney transplant. Transplantation 2006 82 : 853.
33. Fabrizi F, Lunghi G, Dixit V, martin P. Meta-analysis: antiviral therapy of hepatitis c virus-related liver disease in renal transplant patients. Aliment Pharmacol Ther 2006 24 : 1413.
34. Pageaux GP, Hilleret MN, Garrigues V, et al. Pegylated interferon-alpha-based treatment for chronic hepatitis C in renal transplant recipients: an open pilot study. Transplant Int 2009 22 : 562.
35. Barril G, González-Parra E, Alcázar R, et al. Guía sobre enfermedades víricas en hemodiálisis. Nefrología 2004 24 (Suppl. II 43.
36. Cruzado JM, Casanovas-Taltavull T, Torras J, Baliellas C, Gil-Vernet S, Grinyó JM. Pretransplant Interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 2003 3 : 357.
37. Campistol JM, Esforzado N, Morales JM. Hepatitis C virus-positive patients on the waiting list for renal transplantation. Semin Nephrol 2002 22 : 361.
38. Rostaing L, Chatelut E, Payen JL, et al. Pharmacokinetics of alfaIFN-2b in chronic hepatitis C virus patients undergoing chronic haemodialysis or with normal renal function:Clinical implications. J Am Soc Nephrol 1998 9 : 2344.
39. Kamar N, Toupamce O, Buchler M, et al. Evidence that clearance of hepatitis C virus RNA alter alpha interferon therapy in dialysis patients is sustained alter renal transplantation. J Am Soc Nephrol 2003 14 : 2092.
40. Knoll GA, Tankersley MR, Lee JY, et al. The impact of renal transplantation on survival in hepatitis C positive end-stage renal disease patients. Am J Kidney Dis 1997 29 : 606.
41. Abbott KC, Lentine KL, Bucci JR, et al. The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant 2004 4 : 2032.
42. Bloom RD, Sayer G, Fa K, et al. Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list. Am J Transplant 2005 5 : 139.
43. Berenguer M. Treatment of chronic hepatitis C in hemodialysis patients. Hepatology 2008 48 : 1690.
44. Russo MW, Goldsweig CD, Jacobson IM, Brown Jr. RS. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003 98 : 1610.
45. Liu CH, Liang CC, Lin JW, et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut 2008 57 : 525.
46. Rendina M, Schena A, Castellaneta NM, et al. The treatment of chronic hepatitis C with peg-interferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007 46 : 768.
47. Burra P, Buda A, Livi U, et al. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection? Eur J Gastroenterol Hepatol 2006 18 : 1065.
48. Caillard S, Lelong C, Pessione F, Moulin B. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. Am J Transplant 2006 6 : 2735.
49. Caillard S, Agodoa LY, Bohen EM, Abbott KC. Myeloma, Hodgkin disease and lymphoid leukaemia after renal transplantation: characteristics, risk factors and prognosis. Transplantation 2006 27 : 888.
50. Johnson RJ, Wilson R, Yamabe H, et al. Renal manifestations of hepatitis C virus infection. Kidney Int 1994 46 : 1255.
51. Morales JM, Morales E, Andres A, Praga M. Glomerulonephritis associated with hepatitis C virus infection. Curr Opin Nephrol Hypertens 1999 8 : 205.
52. D Amico G. Renal involvement in hepatitis C virus infection: cryoglobulinemic glomerulonephritis. Kidney Int 1998 54 : 650.
53. Morales JM, Campistol JM, Andres A, Rodicio JL. Glomerular diseases in patients with hepatitis C virus infection after renal transplantation. Curr Opin Nephrol Hypertens 1997 6 : 511.
54. Cruzado JM, Gil-Vernet S, Ercilla G, et al. Hepatitis C virus-associated membranoproliferative glomerulonephritis in renal allografts. J Am Soc Nephrol 1996 7 : 2469.
55. Roth D, Cirocco R, Zucker K, et al. De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allografts recipients. Transplantation 1995 59 : 1676.
56. Morales JM, Pascual J, Campistol JM, et al. Membranous glomerulonephritis associated with hepatitis virus infection in renal transplant patients. Transplantation 1997 63 : 1634.
57. Cruzado JM, Carrera M, Torras J, Grinyo JM. Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant 2001 1 : 171.
58. Baid S, Pascual M, Williams Jr. WW, et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C positive allograft recipients. J Am Soc Nephrol 1999 10 : 146.
59. Markowitz GS, Cheng JT, Colvin RB, et al. Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol 1998 9 : 2244.
60. Hestin D, Guillemin F, Castin N, et al. Pre-transplant hepatitis C virus infection: A predictor of proteinuria after renal transplantation. Transplantation 1998 65 : 741.
61. Perico N, Cattaneo D, Bikbov B, et al. Hepatitis infection and chronic renal diseases. Clin J Am Soc Nephrol 2009 4 : 207.
62. Kasuno K, Ono T, Matsumori A, et al. Hepatitis c virus associated tubulo-interstitial injury. Am J Kidney Dis 2003 41 : 767.
63. Hoch B, Jucknevicius I, Liapis H. Glomerular injury associated with hepatitis C infection. A correlation with blood and tissue HCV-PCR. Semin Diag Pathol 2002 19 : 175.
64. Sansonno D, Lauletta G, Montrone M, et al. Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser microdissection. Clin Exper Immunology 2005 140 : 498.
65. Wornle M, Schmid H, Banas B, et al. Novel role of toll-like receptor 3 in hepatitis C-associated glomerulonephritis. Am J Pathol 2006 168 : 370.
66. Basse G, Ribes D, Kamar N, et al. Rituximab therpay for mixed cryoglobulinemia in seven renal transplant patients. Transplant Proc 2006 38 : 2308.
67. Kamar N, Sandres-Sauné K, Rostaing L. Influence of rituximab therapy on hepatitis C virus N concentration in kidney-transplant patients. Am J Translant 2007 7 : 2440.
68. Bestard O, Cruzado JM, Ercilla G, et al. Rituximab induces regression of hepatitis C virus-related membranoprolifertive glomerulonephritis in renal allograft. Nephrol Dial Transplant 2006 21 : 2320.
69. González E, Esforzado N, Usera G, et al. Long-term results of hepatitis C virus-associated glomerular lesions alter renal transplantation. Am J Transplant 2006 Suppl 123 (abstract 167).
70. Sabharwal S, Delgado-Borrego A, Chung RT. Extrahepatic hepatitis C virus after transplantation: diabetes and renal dysfunction. Liver Transpl 2008 14 : S51.
71. Fabrizi F, Messa P, Martin P, et al. Hepatitis C virus infection and post-transplant diabetes mellitus among renal transplant patients: a meta-analysis. Int J Artif Organs 2008 31 : 675.
72. Bloom RD, Rao V, Weng F, et al. Association of hepatitis C with posttransplant diabetes en renal transplant patients on tacrolimus. J Am Soc Nephrol 2002 13 : 1374.
73. Bloom RD, Lake JR. Emerging issues in hepatitis C virus positive liver and kidney transplant recipients. Am J Transplant 2006 6 : 2232.
74. Manzanares C, Moreno M, Castellanos F, et al. Influence of hepatitis C virus infection on FK 506 blood levels in renal transplant patients. Transplant Proc 1998 30 : 1264.
75. Corell A, Morales JM, Mandroño A, et al. Immunosuppression induced by hepatitis C virus infection reduces acute renal transplant rejection. Lancet 1995 346 : 1497.
76. Forman JP, Tolkoff-Rubin N, Pascual M, Lin J. Hepatitis C, acute humoral rejection, and renal allograft survival. J Am Soc Nephrol 2004 15 : 3249.
77. Moreso F, Ibernon M, Goma M, et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006 6 : 747.
78. Rao KV, Ma J. Chronic viral hepatitis enhances the risk of infection but not acute rejection in renal transplant recipients. Transplantation 1996 62 : 1765.
79. Mitwalli AH, Alam A, Al-Wakeel J, et al. Effect of chronic viral hepatitis on graft survival in Saudi renal transplant patients. Nephron Clin Pact 2006 102 : c72.
80. Torres J, Aguado JM, San Juan R, et al. Hepatitis C virus, an important risk factor for tuberculosis in immunocompromised: experiene with kidney transplantation. Transpant Int 2008 21 : 873.
81. Breitenfeldt MK, Rasenak J, Berthold H, et al. Impact of hepatitis B and C on graft loss and mortality of patients after renal transplantation. Clin Transplant 2003 21 : 300.
82. Aroldi A, Lampertico P, Montagnino G, et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 2005 15 : 79. 1132.
83. Meier-Kriesche HU, Ojo AO, Hanson J, et al. Hepatitis C antibody status and outcomes in renal transplant recipients. Transplantation 2001 72 : 241.
84. Mahmoud IM, Elhabashi AF, Elsawy E, et al. The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-year prospective study. Am J Kid Dis 2004 43 : 131.
85. Roth D, Zucker K, Cirocco R, et al. The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int 1994 45 : 238.
86. Pol S, Legendre C, Saltiel C, et al. Hepatitis C virus in kidney recipients, epidemiology and impact of renal transplantation. J Hepatol 1992 15 : 202.
87. Ponz E, Campistol JM, Bruguera M, et al. Hepatitis C virus infection among kidney transplant recipients. Kidney Int 1991 40 : 748.
88. Stehman-Breen CO, Psaty BM, Emerson S, et al. Association of hepatitis C virus infection with mortality and graft survival in kidney-pancreas transplant recipients. Transplantation 1997 64 : 281.
89. Cosio FG, Roche Z, Agrawal A, et al. Prevalence of hepatitis C virus in patients with idiopathic glomerulopathies in native and transplanted kidneys. Am J Kid Dis 1996 28 : 752.
90. Gallay BJ, Alpers CE, Davis Cl, et al. Glomerulonephritis in renal allografts associated with hepatitis C infection: A possible relationship with transplant glomerulopathy in two cases. Am J Kidney Dis 1995 26 : 662.
91. Mahmoud IM, Sobh MA, El-Habashi AF, et al. Interferon therapy in haemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and posttransplantation course. Nephron Clin Pract 2005 100 : c133.
92. Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renal-replacement therapy and outcome after kidney transplantation. Transplantation 2004 78 : 745.
93. Seron D, Arias A, Campistol JM, Morales JM. Late renal allograft failure between 1990 and 1998 in Spain: a changing scenario. Transplantation 2003 76 : 1588.
94. Kasiske BJL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus and kidney transplantation in the United States. Am J Transplant 2003 3 : 178.
95. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after renal transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Transplantation 2003 10 (Suppl SS3.
96. Maluf DG, Fisher RA, King Al, et al. Hepatitis C virus infection and kidney transplantation: predictors of patient and graft survival. Transplantation 2007 83 : 853.
97. Gursoy M, Guvener N, Koksal R, et al. Impact of HCV infection on development of posttransplant diabetes mellitus in renal allograft recipients. Transplant Proc 2000 32 : 561.
98. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989 88 : 359.
99. Pereira BJG, Milford EL, Kirkman RL, Levey AS. Transmission of hepatitis C virus by organ transplantation. N Engl J Med 1991 325 : 454.
100. Pereira BJG, Milford EL, Kirkman RL. Prevalence of HCV RNA in hepatitis C antibody-positive cadaver organ donors and their recipients. N Engl J Med 1992 327 : 910.
101. Diethelm AG, Roth D, Ferguson RM, et al. Transmission of HCV by organ transplantation. N Engl J Med 1992 326 : 410.
102. Roth D, Fernandez JA, Babischkin S, et al. Detection of hepatitis C infection among organ donors: evidence for low transmission of disease. Ann Intern Med 1992 117 : 470.
103. Vincenti F, Lake J, Wright T, Kuo G, Weber P, Stempel C. Nontransmission of hepatitis C from cadaver kidney donors to transplant recipients. Transplantation 1993 55 : 674.
104. Aeder MI, Shield CF, Tegtmeier GE, et al. The incidence and clinical impact of hepatitis C virus (HCV) positive donors in cadaveric transplantation. Transplant Proc 1993 25 : 1469.
105. Tesi RJ, Waller K, Morgan CJ, et al. Transmission of hepatitis C by kidney transplantation: the risks. Transplantation 1994 57 : 826.
106. Morales JM, Campistol JM, Castellano G, et al. Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV. Kidney Int 1995 47 : 236.
107. Ali MK, Light JA, Barhyte DY, et al. Donor hepatitis C virus status does not adversely affect short-term outcomes in HCV+ recipients in renal transplantation. Transplantation 1998 66 : 1694.
108. Mandal AK, Kraus ES, Samaniego M, et al. Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors. Clin Transplant 2000 14 : 679, 91.
109. Woodside KJ, Ishihara K, Theisen JE, et al. Use of kidneys from hepatitis C seropositive donors shortens waitlist time but does not alter one-yr outcome. Clin Transplant 2003 17 : 433.
110. Veroux P, Veroux M, Puliatti C, et al. Kidney transplantation from hepatitis C virus-positive donors into hepatitis C virus-positive recipients: a safe way to expand the donor pool? Transplant Proc 2005 37 : 2571.
111. Veroux P, Veroux M, Sparacino V, et al. Kidney transplantation from donors with viral B and C hepatitis. Transplant Proc 2006 38 : 996.
112. Abbott KC, Bucci JR, Matsumoto CS, et al. Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003 14 : 2908.
113. Abbott KC, Lentine KL, Bucci JR, et al. Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. J Am Soc Nephrol 2004 15 : 3166.
114. Morales JM, Andres A, Campistol JM. Hepatitis C virus and organ transplantation. N Engl J Med 1993 328 : 511.
115. Domínguez-Gil B, Esforzado N, Campistol JM, Andrés A, Morales JM. Use of hepatitis C-positive donors for kidney transplantation. Transplantation Reviews 2007 21 : 195.
116. Schussler T, Staffeld-Coit C, Eason J, Nair S. Severe hepatitis C infection in a renal transplant recipient following hepatitis C genotype mismatch transplant. Am J Transplant 2004 4 : 1375.